Climacteric lowers plasma levels of platelet-derived microparticles: A pilot study in pre-versus postmenopausal women

Abstract

Background: Climacteric increases the risk of thrombotic events by alteration of plasmatic coagulation. Up to now, less is known about changes in platelet-(PMP) and endothelial cell-derived microparticles (EMP). Methods: In this prospective study, plasma levels of microparticles (MP) were compared in 21 premenopausal and 19 postmenopausal women. Results: No altered numbers of total MP or EMP were measured within the study groups. However, the plasma values of CD61-exposing MP from platelets/megakaryocytes were higher in premenopausal women (5,364 × 10 6/l, range 4,384-17,167) as compared to postmenopausal women (3,808 × 10 6/l, range 2,009-8,850; p = 0.020). This differentiation was also significant for the subgroup of premenopausal women without hormonal contraceptives (5,364 × 10 6/l, range 4,223-15,916; p = 0.047; n = 15). Furthermore, in premenopausal women, higher plasma levels of PMP exposing CD62P were also present as compared to postmenopausal women (288 × 10 6/l, range 139-462, vs. 121 × 10 6/l, range 74-284; p = 0.024). This difference was also true for CD63+ PMP levels (281 × 10 6/l, range 182-551, vs. 137 × 10 6/l, range 64-432; p = 0.015). Conclusion: Climacteric lowers the level of PMP but has no impact on the number of EMP in women. These data suggest that PMP and EMP do not play a significant role in enhancing the risk of thrombotic events in healthy, postmenopausal women. © 2012 S. Karger AG, Basel.